股本结构
单位:万股
公告日期 | 2023-08-09 | 2023-06-02 | 2023-05-11 | 2023-04-27 | 2023-05-11 | 2023-03-15 |
---|---|---|---|---|---|---|
证券总股本 | 124.21 | 121.69 | 2433.77 | 2434.32 | 2433.78 | 2433.77 |
普通股本 | 124.21 | 121.69 | 2433.77 | 2434.32 | 2433.78 | 2433.77 |
优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
变动日期 | 2023-06-30 | 2023-06-05 | 2023-05-09 | 2023-04-24 | 2023-03-31 | 2022-12-31 |
注释:中概股证券总股本=普通股股本/
存托凭证比例
历史变动
公告日期 | 变动后普通股本(万股) | 变动后优先股(万股) | 变动原因 | 变动日期 |
---|---|---|---|---|
2023-08-09 | 124.21 | 未披露 | 定期报告 | 2023-06-30 |
2023-06-02 | 121.69 | 未披露 |
更多>>
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-20 reverse stock split of its outstanding and authorized shares of common stock.
|
2023-06-05 |
2023-05-11 | 2433.77 | 未披露 | 定期报告 | 2023-05-09 |
2023-04-27 | 2434.32 | 未披露 | 定期报告 | 2023-04-24 |
2023-05-11 | 2433.78 | 未披露 | 定期报告 | 2023-03-31 |
2023-03-15 | 2433.77 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Compensation expense for issuance of restricted stock to employees
Interest payment for convertible notes
|
2022-12-31 |
2022-11-14 | 2433.78 | 未披露 | 定期报告 | 2022-11-10 |
2022-11-14 | 2433.27 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Compensation expense for issuance of restricted stock to employees
|
2022-09-30 |
2022-09-12 | 2433.84 | 未披露 | 定期报告 | 2022-09-09 |
2022-08-09 | 2427.77 | 未披露 | 定期报告 | 2022-08-05 |
2022-08-09 | 2427.19 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Interest payment for convertible notes
|
2022-06-30 |
2022-04-28 | 1328.56 | 未披露 | 定期报告 | 2022-04-13 |
2022-05-13 | 1327.97 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Compensation expense for issuance of restricted stock to employees
|
2022-03-31 |
2022-03-18 | 1325.03 | 未披露 | 定期报告 | 2022-03-09 |
2022-03-18 | 1324.43 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Compensation expense and issuance of restricted stock to employees
Interest payment for convertible notes
|
2021-12-31 |
2021-11-12 | 1120.22 | 未披露 | 定期报告 | 2021-11-05 |
2021-11-12 | 1118.82 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Compensation expense and issuance of restricted stock to employees
Compensation expense for issuance of stock options to employees
|
2021-09-30 |
2021-08-12 | 1112.41 | 未披露 | 定期报告 | 2021-08-06 |
2021-08-12 | 1110.65 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Interest payment for convertible notes
|
2021-06-30 |
2021-05-12 | 948.86 | 未披露 | 定期报告 | 2021-05-07 |
2021-04-23 | 948.99 | 未披露 | 定期报告 | 2021-04-15 |
2021-04-23 | 948.90 | 未披露 | 定期报告 | 2021-04-05 |
2021-05-12 | 947.07 | 未披露 | 定期报告 | 2021-03-31 |
2021-03-16 | 948.99 | 未披露 | 定期报告 | 2021-03-04 |
2021-01-13 | 948.32 | 未披露 | 定期报告 | 2021-01-07 |
2020-12-31 | 799.37 | 未披露 |
更多>>
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-6 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time today, and the Company’s common stock will begin trading on a split-adjusted basis at the market open on January 4, 2021.
|
2021-01-04 |
2020-11-06 | 4796.24 | 未披露 | 定期报告 | 2020-10-30 |
2020-11-06 | 4770.48 | 未披露 | 定期报告 | 2020-09-30 |
2020-09-11 | 4796.82 | 未披露 | 定期报告 | 2020-09-09 |
2020-09-11 | 4797.91 | 未披露 | 定期报告 | 2020-07-22 |
2020-08-10 | 4770.48 | 未披露 | 定期报告 | 2020-06-30 |
2020-06-29 | 4798.11 | 未披露 | 定期报告 | 2020-06-26 |
2020-07-06 | 4798.11 | 未披露 | 定期报告 | 2020-06-19 |
2020-05-08 | 4798.45 | 未披露 | 定期报告 | 2020-05-04 |
2020-04-28 | 4798.53 | 未披露 | 定期报告 | 2020-04-20 |
2020-05-08 | 4770.48 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Compensation expense for issuance of restricted stock to employees
|
2020-03-31 |
2020-04-28 | 4799.18 | 未披露 | 定期报告 | 2020-03-15 |
2020-02-28 | 4799.70 | 未披露 | 定期报告 | 2020-02-20 |
2020-02-28 | 4770.11 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Purchase of Treasury Stock
|
2019-12-31 |
2019-11-07 | 4803.02 | 未披露 | 定期报告 | 2019-10-31 |
2019-11-07 | 4751.06 | 未披露 |
更多>>
From June 30, 2019 to September 30, 2019
Compensation expense for issuance of restricted stock to employees
|
2019-09-30 |
2019-08-07 | 4810.80 | 未披露 | 定期报告 | 2019-07-31 |
2019-08-07 | 4750.56 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Compensation expense for issuance of restricted stock to employees
Adjustments to Treasury Stock
Purchase of Treasury Stock
|
2019-06-30 |
2019-05-07 | 4812.97 | 未披露 | 定期报告 | 2019-05-01 |
2019-04-26 | 4809.96 | 未披露 | 定期报告 | 2019-04-22 |
2019-05-07 | 4747.16 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Purchase of Treasury Stock
|
2019-03-31 |
2019-04-26 | 4808.70 | 未披露 | 定期报告 | 2019-03-15 |
2019-02-27 | 4763.34 | 未披露 | 定期报告 | 2019-02-20 |
2019-02-27 | 4742.08 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Purchase of Treasury Stock
|
2018-12-31 |
2018-11-06 | 4755.83 | 未披露 | 定期报告 | 2018-10-31 |
2018-11-06 | 4723.10 | 未披露 | 定期报告 | 2018-09-30 |
2018-08-08 | 4748.38 | 未披露 | 定期报告 | 2018-07-31 |
2018-08-08 | 4714.38 | 未披露 | 定期报告 | 2018-06-30 |
2018-05-09 | 4706.65 | 未披露 | 定期报告 | 2018-05-07 |
2018-04-27 | 4705.98 | 未披露 | 定期报告 | 2018-04-25 |
2018-05-09 | 4666.16 | 未披露 | 定期报告 | 2018-03-31 |
2018-04-27 | 4700.14 | 未披露 | 定期报告 | 2018-03-15 |
2018-03-01 | 4691.38 | 未披露 | 定期报告 | 2018-02-20 |
2018-03-01 | 4642.53 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
|
2017-12-31 |
2017-11-07 | 4674.72 | 未披露 | 定期报告 | 2017-10-31 |
2017-11-07 | 4670.43 | 未披露 | 定期报告 | 2017-09-30 |
2017-08-08 | 4665.07 | 未披露 | 定期报告 | 2017-07-31 |
2017-08-08 | 4664.08 | 未披露 | 定期报告 | 2017-06-30 |
2017-05-09 | 4665.94 | 未披露 | 定期报告 | 2017-04-30 |
2017-05-09 | 4675.82 | 未披露 | 定期报告 | 2017-03-31 |
2017-04-21 | 4676.04 | 未披露 | 定期报告 | 2017-03-15 |
2017-02-27 | 4640.79 | 未披露 | 定期报告 | 2017-02-17 |
2017-02-27 | 4566.76 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Private placement, net of issuance costs
|
2016-12-31 |
2016-11-07 | 4611.43 | 未披露 | 定期报告 | 2016-10-31 |
2016-11-07 | 4613.25 | 未披露 | 定期报告 | 2016-09-30 |
2016-08-04 | 4613.99 | 未披露 | 定期报告 | 2016-07-29 |
2016-08-04 | 4609.09 | 未披露 | 定期报告 | 2016-06-30 |
2016-05-06 | 4606.73 | 未披露 | 定期报告 | 2016-04-30 |
2016-04-29 | 4595.73 | 未披露 | 定期报告 | 2016-04-11 |
2016-05-06 | 4596.25 | 未披露 | 定期报告 | 2016-03-31 |
2016-02-29 | 4574.93 | 未披露 | 定期报告 | 2016-02-17 |
2016-02-29 | 4298.70 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
|
2015-12-31 |
2015-11-09 | 4315.54 | 未披露 | 定期报告 | 2015-10-31 |
2015-11-09 | 4287.67 | 未披露 | 定期报告 | 2015-09-30 |
2015-08-07 | 4284.63 | 未披露 | 定期报告 | 2015-07-31 |
2015-08-07 | 4281.74 | 未披露 | 定期报告 | 2015-06-30 |
2015-05-08 | 4279.09 | 未披露 | 定期报告 | 2015-04-30 |
2015-04-30 | 4279.72 | 未披露 | 定期报告 | 2015-04-13 |
2015-05-08 | 4278.56 | 未披露 | 定期报告 | 2015-03-31 |
2015-02-27 | 4257.54 | 未披露 | 定期报告 | 2015-02-17 |
2015-02-27 | 4187.14 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
|
2014-12-31 |
2014-11-07 | 4194.80 | 未披露 | 定期报告 | 2014-10-31 |
2014-11-07 | 4122.42 | 未披露 | 定期报告 | 2014-09-30 |
2014-08-07 | 4174.49 | 未披露 | 定期报告 | 2014-07-31 |
2014-08-07 | 4106.05 | 未披露 | 定期报告 | 2014-06-30 |
2014-05-09 | 4164.59 | 未披露 | 定期报告 | 2014-04-30 |
2014-04-25 | 4165.36 | 未披露 | 定期报告 | 2014-04-08 |
2014-05-09 | 4102.81 | 未披露 | 定期报告 | 2014-03-31 |
2014-03-03 | 4131.08 | 未披露 | 定期报告 | 2014-02-14 |
2014-03-03 | 4088.39 | 未披露 |
更多>>
From December 31,2012 to December 31,2013
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
|
2013-12-31 |
2013-11-07 | 4127.46 | 未披露 | 定期报告 | 2013-10-31 |
2013-11-07 | 4061.12 | 未披露 | 定期报告 | 2013-09-30 |
2013-08-08 | 4069.35 | 未披露 | 定期报告 | 2013-07-31 |
2013-08-08 | 4004.21 | 未披露 | 定期报告 | 2013-06-30 |
2013-05-10 | 4056.61 | 未披露 | 定期报告 | 2013-04-30 |
2013-04-19 | 4054.70 | 未披露 | 定期报告 | 2013-04-02 |
2013-05-10 | 3988.10 | 未披露 | 定期报告 | 2013-03-31 |
2013-02-28 | 4028.01 | 未披露 | 定期报告 | 2013-02-15 |
2013-02-28 | 3979.21 | 未披露 |
更多>>
from December 31, 2011 to December 31, 2012
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
|
2012-12-31 |
2012-11-08 | 4015.77 | 未披露 | 定期报告 | 2012-10-31 |
2012-11-08 | 3948.17 | 未披露 | 定期报告 | 2012-09-30 |
2012-08-08 | 4009.33 | 未披露 | 定期报告 | 2012-07-31 |
2012-08-08 | 3945.47 | 未披露 | 定期报告 | 2012-06-30 |
2012-05-09 | 4009.62 | 未披露 | 定期报告 | 2012-04-30 |
2012-05-09 | 3941.04 | 未披露 | 定期报告 | 2012-03-31 |
2012-02-28 | 3970.11 | 未披露 | 定期报告 | 2012-02-15 |
2012-02-28 | 3931.61 | 未披露 |
更多>>
FROM December 31, 2010 TO December 31, 2011
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
|
2011-12-31 |
2011-11-07 | 3966.75 | 未披露 | 定期报告 | 2011-10-31 |
2011-11-07 | 3910.89 | 未披露 | 定期报告 | 2011-09-30 |
2011-08-08 | 3965.77 | 未披露 | 定期报告 | 2011-07-31 |
2011-08-08 | 3909.44 | 未披露 | 定期报告 | 2011-06-30 |
2011-05-09 | 3946.20 | 未披露 | 定期报告 | 2011-04-30 |
2011-05-09 | 3879.58 | 未披露 | 定期报告 | 2011-03-31 |
2011-03-01 | 3910.12 | 未披露 | 定期报告 | 2011-02-17 |
2011-03-01 | 3876.70 | 未披露 |
更多>>
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
|
2010-12-31 |
2010-11-09 | 3907.97 | 未披露 | 定期报告 | 2010-10-31 |
2010-11-09 | 3856.84 | 未披露 |
更多>>
Vested and expected to vest at September 30, 2010
Vested and exercisable at September 30, 2010
|
2010-09-30 |
2010-08-09 | 3887.57 | 未披露 | 定期报告 | 2010-07-31 |
2010-08-09 | 3835.25 | 未披露 |
更多>>
Vested and expected to vest at June 30, 2010
Vested and exercisable at June 30, 2010
|
2010-06-30 |
2010-05-10 | 3872.11 | 未披露 | 定期报告 | 2010-04-30 |
2010-05-10 | 3825.17 | 未披露 |
更多>>
Vested and expected to vest at March 31, 2010
Vested and exercisable at March 31, 2010
|
2010-03-31 |
2010-02-26 | 3816.13 | 未披露 | 定期报告 | 2010-02-19 |
2010-02-26 | 3793.51 | 未披露 |
更多>>
from December 31, 2008 to December 31, 2009
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
|
2009-12-31 |
2009-03-02 | 3777.47 | 未披露 | 定期报告 | 2009-02-13 |
2009-03-02 | 3761.34 | 未披露 |
更多>>
from December 31, 2007 to December 31, 2008
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Common stock issued pursuant to follow-on offerings, net of offering costs of $9,686,600
Stock issued pursuant to NRI asset acquisition
|
2008-12-31 |
2008-03-14 | 3245.84 | 未披露 | 定期报告 | 2008-02-22 |
2008-03-14 | 2857.47 | 未披露 |
更多>>
from December 31, 2006 to December 31, 2007
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Common stock issued pursuant to follow-on offering, net of offering costs of $5,290,961
Common stock issued pursuant to exercise of warrants
|
2007-12-31 |
2007-05-08 | 2412.50 | 未披露 | 定期报告 | 2007-03-01 |
2007-03-26 | 2371.64 | 未披露 | 定期报告 | 2007-02-28 |
2007-03-26 | 2365.78 | 未披露 |
更多>>
from December 31, 2005 to December 31, 2006
Conversion convertible preferred stock to common stock
Common stock issued pursuant to IPO, net of offering costs of $4,994,373
Common stock issued pursuant to private placement, net of offering costs of $1,718,584
Common stock issued pursuant to cashless exercise of warrants
Common stock issued pursuant to conversion of convertible
|
2006-12-31 |
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-20 reverse stock split of its outstanding and authorized shares of common stock.
From December 31, 2021 to December 31, 2022
Compensation expense for issuance of restricted stock to employees
Interest payment for convertible notes
From June 30, 2022 to September 30, 2022
Compensation expense for issuance of restricted stock to employees
From March 31, 2022 to June 30, 2022
Interest payment for convertible notes
From December 31, 2021 to March 31, 2022
Compensation expense for issuance of restricted stock to employees
From December 31, 2020 to December 31, 2021
Compensation expense and issuance of restricted stock to employees
Interest payment for convertible notes
From June 30, 2021 to September 30, 2021
Compensation expense and issuance of restricted stock to employees
Compensation expense for issuance of stock options to employees
From March 31, 2021 to June 30, 2021
Interest payment for convertible notes
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-6 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time today, and the Company’s common stock will begin trading on a split-adjusted basis at the market open on January 4, 2021.
From December 31, 2019 to March 31, 2020
Compensation expense for issuance of restricted stock to employees
From December 31, 2018 to December 31, 2019
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Purchase of Treasury Stock
From June 30, 2019 to September 30, 2019
Compensation expense for issuance of restricted stock to employees
From March 31, 2019 to June 30, 2019
Compensation expense for issuance of restricted stock to employees
Adjustments to Treasury Stock
Purchase of Treasury Stock
from December 31, 2018 to March 31, 2019
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Purchase of Treasury Stock
from December 31, 2017 to December 31, 2018
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Purchase of Treasury Stock
from December 31, 2016 to December 31, 2017
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
from December 31, 2015 to December 31, 2016
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Private placement, net of issuance costs
from December 31, 2014 to December 31, 2015
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
from December 31, 2013 to December 31, 2014
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
From December 31,2012 to December 31,2013
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
from December 31, 2011 to December 31, 2012
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
FROM December 31, 2010 TO December 31, 2011
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Vested and expected to vest at September 30, 2010
Vested and exercisable at September 30, 2010
Vested and expected to vest at June 30, 2010
Vested and exercisable at June 30, 2010
Vested and expected to vest at March 31, 2010
Vested and exercisable at March 31, 2010
from December 31, 2008 to December 31, 2009
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
from December 31, 2007 to December 31, 2008
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Common stock issued pursuant to follow-on offerings, net of offering costs of $9,686,600
Stock issued pursuant to NRI asset acquisition
from December 31, 2006 to December 31, 2007
Compensation expense for issuance of restricted stock to employees
Exercise of stock options
Common stock issued pursuant to follow-on offering, net of offering costs of $5,290,961
Common stock issued pursuant to exercise of warrants
from December 31, 2005 to December 31, 2006
Conversion convertible preferred stock to common stock
Common stock issued pursuant to IPO, net of offering costs of $4,994,373
Common stock issued pursuant to private placement, net of offering costs of $1,718,584
Common stock issued pursuant to cashless exercise of warrants
Common stock issued pursuant to conversion of convertible